US4725673AExpiredUtility

Plasma fraction purification using silica resin bound to a ligand

61
Assignee: ALPHA THERAPEUTIC CORPPriority: Aug 29, 1986Filed: Aug 29, 1986Granted: Feb 16, 1988
Est. expiryAug 29, 2006(expired)· nominal 20-yr term from priority
Inventors:Steven W. Herring
Y10S530/83C12N 9/647A61K 38/00B01D 15/3823
61
PatentIndex Score
23
Cited by
24
References
28
Claims

Abstract

There is provided, in accordance with practice of this invention, a process for separating Factor IX and/or Factor X from an impure protein fraction containing protein in addition to Factors IX and X. A silica resin coupled with a ligand capable of binding Factor IX and/or Factor X is provided. An aqueous solution of the impure protein fraction is applied to the ligand-coupled silica resin to thereby bind the Factor IX and/or Factor X to the resin. The Factor IX and/or Factor X is then recovered from the resin by elution.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
       1. A process for separating Factor IX from an impure protein fraction containing Factor IX, the process including the steps of: providing an aqueous solution of the impure protein fraction;   applying the impure protein fraction solution to a chromatographic column containing a silica resin coupled with a ligand capable of binding Factor IX;   binding Factor IX to the ligand; and   recovering Factor IX from the column.   
     
     
       2. The process according to claim 1 wherein the ligand is dextran sulfate. 
     
     
       3. The process according to claim 1 wherein the ligand is heparin. 
     
     
       4. The process according to claim 1 wherein the ligand is dermatan sulfate. 
     
     
       5. The process according to claim 1 wherein the ligand is heparan sulfate. 
     
     
       6. The process according to claim 1 wherein the impure protein fraction is prothrombin comprising Factor II, Factor VII, Factor IX and Factor X. 
     
     
       7. The process according to claim 1 wherein the silica resin has a particle size of from about 1 micron to about 1000 microns. 
     
     
       8. The process according to claim 1 wherein the silica resin has a particle size of from about 100 microns to about 200 microns. 
     
     
       9. A process for separating of Factor X from an impure protein faction containing Factor X, the process including the steps of: providing an aqueous solution of the impure protein fraction;   applying the impure protein fraction solution to a chromatographic column containing a silica resin coupled with a ligand capable of binding Factor X;   binding Factor X to the ligand; and   recovering Factor X from the column.   
     
     
       10. The process according to claim 9 wherein the ligand is dextran sulfate. 
     
     
       11. The process according to claim 9 wherein the ligand is heparin. 
     
     
       12. The process according to claim 9 wherein the ligand is dermatin sulfate. 
     
     
       13. The process according to claim 9 wherein the ligand is heparan sulfate. 
     
     
       14. The process according to claim 9 wherein the impure protein fraction is prothrombin comprising Factor II, Factor VII, Factor IX and Factor X. 
     
     
       15. The process according to claim 9 wherein the silica resin has a particle size of from about 1 micron to about 1000 microns. 
     
     
       16. The process according to claim 9 wherein the silica resin has a particle size of from about 100 microns to about 200 microns. 
     
     
       17. A process for separating Factor IX from an impure protein fraction containing Factor IX, the process including the steps of: preparing an aqueous solution of the impure protein fraction;   preparing a silica resin coupled with a ligand capable of binding Factor IX;   applying the impure protein fraction solution to the ligand-coupled silica resin;   binding Factor IX to the ligand; and   recovering Factor IX from the resin.   
     
     
       18. the process according to claim 17 wherein the ligand is dextran sulfate. 
     
     
       19. The process according to claim 17 wherein the ligand is heparin. 
     
     
       20. The process according to claim 17 wherein the ligand is dermatan sulfate. 
     
     
       21. The process according to claim 17 wherein the ligand is heparan sulfate. 
     
     
       22. The process according to claim 17 wherein the impure protein fraction is prothrombin comprising Factor II, Factor VII, Factor IX and Factor X. 
     
     
       23. A process for separating of Factor X from an impure protein faction containing Factor X, the process including the steps of: preparing an aqueous solution of the impure protein fraction;   preparing a silica resin coupled with a ligand capable of binding Factor X;   applying the impure protein fraction solution to the ligand coupled silica resin;   binding Factor X to the ligand; and   recovering Factor X from the resin.   
     
     
       24. The process according to claim 23 wherein the ligand is dextran sulfate. 
     
     
       25. The process according to claim 23 wherein the ligand is heparin. 
     
     
       26. The process according to claim 23 wherein the ligand is dermatan sulfate. 
     
     
       27. The process according to claim 23 wherein the ligand is heparan sulfate. 
     
     
       28. The process according to claim 23 wherein the impure protein fraction is prothrombin comprising Factor II, Factor VII, Factor IX and Factor X.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.